venlafaxine Articles
US FDA approves Teva’s generic venlafaxine, the first copy version of Pfizer’s Effexor XR
30 June 2010
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Pfizer 2009 3rd-qtr earnings beats forecasts, but sales weaken
21 October 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Wyeth's first-quarter 2009 profit flat year-on-year as it prepares for Pfizer mega-merger
29 April 2009
Lyrica fares well vs venlafaxine-ER in GAD
30 March 2009
Data on withdrawn drugs was faked; says hospital
16 March 2009
Lexapro and Zoloft are "best" antidepressants
9 February 2009
Mylan gets US appro for generic Effexor
24 November 2008
Wyeth's 3rd-qtr profit flat; AD drug delayed
3 November 2008
Wyeth pulls European MAA for desvenlafaxine
20 October 2008
Wyeth and Impax reach Effexor accord
28 July 2008
FDA approves Mylan's generic Effexor
23 June 2008
FDA OKs Osmoteca's venlafaxine ER
2 June 2008
Wyeth beats forecasts despite generics
5 May 2008
Mylan seeks more generic market share
7 April 2008
Wyeth's 4th-qtr 2007 income climbs 18% just shy of estimates; predicts flat 2008 on generic competition
11 February 2008
Lilly hits back at data suppression claims
28 January 2008
Japan stock market week toJan 14, 2008
21 January 2008
Patent expiry for 2008 provides generic opportunity
14 January 2008
New head of Wyeth France to manage future growth
29 October 2007
Stock Commentary - New York week to July 30, 2007
6 August 2007
Sepracor files Lunivia MAA with EMEA
6 August 2007
Wyeth's 2nd-qtr net income climbs 12.5%
30 July 2007
Wyeth's 1st-qtr income up 12% to $1.25B
30 April 2007
Wyeth's income up 17%, but shares fall 2.5%
5 February 2007
Patent expiries will stem growth of antidepressants market
18 December 2006
US FDA issues overdose warning on Effexor
6 November 2006
Wyeth's income climbs 33% to $1.16B in 3rd-qtr, on continued success of Enbrel and Prevnar
30 October 2006
FDA approves generic venlafaxine
14 August 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
Wyeth's 1st-qtr 2006 revenues $4.8B, up 6%
1 May 2006
Wyeth moves into profit but disapoints
6 February 2006
Stock Commentary - New York week to Dec 5
12 December 2005
Danger to patients from weak US Rx system: CU
12 December 2005
Wyeth launches Effexor patient support campaign
22 August 2005
USA
22 August 2005
US FDA posts DSOB meeting summary
15 August 2005
Enbrel drives Wyeht's 2nd-qtr sales
1 August 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Stock Commentary - New York
4 April 2005
Fen-phem charges gouge Wyeth results
7 February 2005
Stock Commentary - New York
7 February 2005
Wyeth's 2nd-qtr profit slips, but sales climb
26 July 2004
Lundbeck's Cipralex as effective as rival drug
21 June 2004
Stock Commentary - New York
31 May 2004
Wyeth posts 9% rise in 1st-qtr revenue
3 May 2004
Wyeth and Solvay enter CNS collaboration
12 April 2004
Charges pull Wyeth earnings down 79%
2 February 2004
Stock Commentary - New York
2 February 2004
Wyth sees 3rd-quarter loss on charges
27 October 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Profits up at Wyeth, HRT sales still suffering
28 April 2003
Effexor cleared for social phobia in USA
17 February 2003
Earnings up at Wyeth, HRT drugs sluggish
3 February 2003
Stock Commentary - New York
5 August 2002
Wyeth EPS increases 25% during 2nd qtr
29 July 2002
Wyeth hit as Prempro linked to cancer, CVD
15 July 2002
AHP overcomes fen-phen problems to post strong growth for 2001
4 February 2002
AHP takes $950 mill fen-phen charge
24 October 2001
AHP posts 16% 1st-qtr earnings rise, sales up 6%
25 July 2001
New AHP CEO reviews growth strategy
25 May 2001
Stock Commentary - New York
17 May 2001
AHP's Effexor approved for extended use in USA
11 May 2001
AHP's Effexor approvable for new uses
27 April 2001
New drug sales boost AHP's 1st-qtr profits
26 April 2001
AHP takes $7.5 billion charge for fen-phen
26 January 2001
AHP reaping benefits of R&D spend
20 October 2000
AHP posts healthy 2nd quarter results
24 July 2000
AHP posts 18% net income growth
20 April 2000
Effexor "more effective" than Prozac, says study
17 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
